膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Annexin A2 (ANXA2) ,etc. by FLIA (Flow Luminescence Immunoassay)
ANX-A2; ANX2L4; CAL1H; LIP2; LPC2; LPC2D; P36; PAP-IV; Protein I; Chromobindin-8; Calpactin-1 heavy chain; Lipocortin II; Placental anticoagulant protein IV
（注：單次混測多因子不超過8個(gè)指標(biāo) ）
- 編號ULMB944Ra
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長3.5h
- 檢測范圍7.81-8000pg/mL
- 靈敏度最小可檢測劑量小于等于2.603 pg/mL.
- 樣本類型Serum, plasma and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 1351 ¥ 1403 ¥ 1481 ¥ 1585 ¥ 1689 ¥ 1845 ¥ 2078 ¥ 2598 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測定并計(jì)算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 89-98 | 95 |
| EDTA plasma(n=5) | 96-105 | 99 |
| heparin plasma(n=5) | 89-98 | 93 |
| sodium citrate plasma(n=5) | 95-105 | 101 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個(gè)樣本使用同一試劑盒重復(fù)測定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 86-101% | 80-104% | 95-103% | 93-101% |
| EDTA plasma(n=5) | 88-98% | 83-98% | 84-98% | 96-105% |
| heparin plasma(n=5) | 78-101% | 91-103% | 87-98% | 79-101% |
| sodium citrate plasma(n=5) | 95-105% | 92-105% | 98-105% | 87-96% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠）標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，
37°C酶標(biāo)板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測溶液A100μL，37°C酶標(biāo)板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測溶液B100μL，37°C振動孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
相關(guān)產(chǎn)品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPB944Ra01 | 膜聯(lián)蛋白A2(ANXA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAB944Ra01 | 膜聯(lián)蛋白A2(ANXA2)多克隆抗體 | WB; IHC; ICC; IP. |
| UMAB944Ra21 | 膜聯(lián)蛋白A2(ANXA2)單克隆抗體 | WB; IHC; ICC; IP. |
| USEB944Ra | 膜聯(lián)蛋白A2(ANXA2)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMB944Ra | 膜聯(lián)蛋白A2(ANXA2)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Journal of Cellular Biochemistry | Subcellular proteome analysis unraveled annexin A2 related to immune liver fibrosis [PubMed: 20225235] |
| World Journal of Gastroenterology | Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma [PubMed: PMC3491596] |
| Oncology Letters | Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis [PubMed: PMC3742823] |
| Ibrahim | Annexin A2 Versus Afp as An Efficient Diagnostic Serum Marker for Hepatocellular Carcinoma [Ghrnet: Source] |
| European Journal of Clinical Microbiology & Infectious Diseases | Serum annexin A2 levels in acute brucellosis and brucellar spondylodiscitis [Pubmed:24853056] |
| Biomedicine & Pharmacotherapy | Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables [Pubmed:25661364] |
| Hepat Mon | Serum Levels of Annexin A2 as a Candidate Biomarker for Hepatic Fibrosis in Patients With Chronic Hepatitis B [PubMed: 26587036] |
| Tumour Biol | Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma [PubMed: 26109000] |
| Biomed Pharmacother | Circulating [PubMed: 25661364] |
| Tumour Biol | Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma [PubMed: 26189841] |
| Eur J Clin Invest | Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population [PubMed: 26081791] |
| Journal of Oral and Maxillofacial Surgery | Serum?Annexin?A2?Level?Is?Associated?With?Diagnosis?and?Prognosis?in?Patients?With?OralSquamous?Cell?Carcinoma. [pubmed:27889534] |
| Pregnancy Hypertens | Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study. [pubmed:28501283] |
| Mol Nutr Food Res. | Epigallocatechin gallate induces an up-regulation of LDL receptor accompanied by a reduction of PCSK9 via the annexin A2-independent pathway in HepG2 cells. [pubmed:28181408] |
| Archives of Gynecology and Obstetrics | Expression of annexin A2 in adenomyosis and dysmenorrhea [Pubmed: 31183557] |
| Cancers | Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer [Pubmed: 31842290] |
| PLASMA BIOMARKER FOR OVARIAN CANCER [] | |
| Diagnostics | Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer. Diagnostics 2021, 11, 69 [33406648] |
| ADVANCED RESEARCHES | Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C [] |
| Cancer Cell International | Bufalin Induced Mitochondrial Dysfunction Promotes Apoptosis of Glioma Cells by Regulating Annexin A2 and DRP1 Proteins [] |
| Cancer Cell Int | Bufalin induces mitochondrial dysfunction and promotes apoptosis of glioma cells by regulating Annexin A2 and DRP1 protein expression [34376212] |
